398 related articles for article (PubMed ID: 33705871)
1. Targeting the acetylation signaling pathway in cancer therapy.
Dang F; Wei W
Semin Cancer Biol; 2022 Oct; 85():209-218. PubMed ID: 33705871
[TBL] [Abstract][Full Text] [Related]
2. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
3. Nonhistone protein acetylation as cancer therapy targets.
Singh BN; Zhang G; Hwa YL; Li J; Dowdy SC; Jiang SW
Expert Rev Anticancer Ther; 2010 Jun; 10(6):935-54. PubMed ID: 20553216
[TBL] [Abstract][Full Text] [Related]
4. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
5. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
7. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.
Schuetze KB; McKinsey TA; Long CS
J Mol Cell Cardiol; 2014 May; 70():100-7. PubMed ID: 24631770
[TBL] [Abstract][Full Text] [Related]
8. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
9. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
Dekker FJ; van den Bosch T; Martin NI
Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
[TBL] [Abstract][Full Text] [Related]
11. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
12. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
Spange S; Wagner T; Heinzel T; Krämer OH
Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
[TBL] [Abstract][Full Text] [Related]
13. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
Li Z; Zhu WG
Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
[TBL] [Abstract][Full Text] [Related]
14. The role of protein acetylation in carcinogenesis and targeted drug discovery.
Yang J; Song C; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972312. PubMed ID: 36171897
[TBL] [Abstract][Full Text] [Related]
15. Regulation of protein turnover by acetyltransferases and deacetylases.
Sadoul K; Boyault C; Pabion M; Khochbin S
Biochimie; 2008 Feb; 90(2):306-12. PubMed ID: 17681659
[TBL] [Abstract][Full Text] [Related]
16. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
Langley B; Gensert JM; Beal MF; Ratan RR
Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
[TBL] [Abstract][Full Text] [Related]
17. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of histone deacetylases (HDACs) in UPR regulation.
Kahali S; Sarcar B; Chinnaiyan P
Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
[TBL] [Abstract][Full Text] [Related]
20. Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke.
Xu Y; Wang Q; Chen J; Ma Y; Liu X
Dis Markers; 2020; 2020():8820803. PubMed ID: 32963637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
